

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 November 2020 (26.11.2020)



(10) International Publication Number
WO 2020/236940 A1

(51) International Patent Classification:

C07D 487/10 (2006.01) C07D 403/14 (2006.01)
C07D 491/107 (2006.01) A61K 31/517 (2006.01)
C07D 495/10 (2006.01) A61K 31/527 (2006.01)
C07D 498/10 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/033816

(22) International Filing Date:

20 May 2020 (20.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/850,289 20 May 2019 (20.05.2019) US

(71) Applicants: CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1200 E. California Boulevard, Mail Code 210-85, Pasadena, CA 91125 (US). 1200 PHARMA LLC [—/US]; 844 East Green Street, Suite 204, Pasadena, CA 91101 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US).

(72) Inventors: HILF, Justin, A.; 104 Westmont Drive, Alhambra, CA 91801 (US). ROSE, Tristin, E.; 4210 Via Arbolada #207, Los Angeles, CA 90042 (US). BARTBERGER, Michael, D.; 4471 Ventura Canyon Ave., #D-105, Sherman Oaks, CA 91423 (US). O'BOYLE, Brendan, M.; 247 El Nido Ave., Monrovia, CA 91016 (US). REEVES, Corey, M.; 4634 Prospect Ave., Los Angeles, CA 90027 (US). LOSON, Oliver, C.; 534 W. Lime Ave., Monrovia, CA 91016 (US). STOLTZ, Brian, M.; 1954 E. California Blvd., San Marino, CA 91108 (US). MCDERMOTT, Martina, S.; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). O'BRIEN, Neil, A.; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US). SLAMON, Dennis; 10889 Wilshire Blvd. Suite 920, Los Angeles, CA 90095-7191 (US).

(74) Agent: HALSTEAD, David, P. et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: KRAS G12C INHIBITORS AND USES THEREOF

(57) Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

WO 2020/236940 A1